Antibody neutralization and escape by HIV-1

Nature

Volumn 422, Issue 6929, 2003, Pages 307-312

  Wei, Xiping ^a   Decker, Julie M ^a   Wang, Shuyi ^a   Hui, Huxiong ^b   Kappes, John C ^b,c   Wu, Xiaoyun ^b   Salazar Gonzalez, Jesus F ^b   Salazar, Maria G ^b   Kilby, J Michael ^b   Saag, Michael S ^b   Komarova, Natalia L ^d   Nowak, Martin A ^d   Hahn, Beatrice H ^b,c   Kwong, Peter D ^e   Shaw, George M ^a,b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d INSTITUTE FOR ADVANCED STUDY   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGY; PATHOLOGY; VIRUSES;

GLYCOSYLATION;

ANTIBODIES;

EPITOPE; GLYCAN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

HUMAN IMMUNODEFICIENCY VIRUS; MEDICINE;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; ENVELOPE GENE; GENE MAPPING; GENE MUTATION; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; RECEPTOR BINDING; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD4; EPITOPES; GLYCOSYLATION; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE SERA; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTAGENESIS; NEUTRALIZATION TESTS; TIME FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0037456827     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature01470     Document Type: Article

References (30)

1. Albert, J. et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4, 107-112 (1990).
2. Pilgrim, A. K. et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176, 924-932 (1997).
3. Moog, C., Fleury, H. J. A., Pellegrin, I., Kirn, A. & Aubertin, A. M. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol 71, 3734-3741 (1997).
4. Montefiori, D. C., Hill, T. S., Vo, H. T. T., Walker, B. D. & Rosenberg, E. S. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J. Virol. 75, 10200-10207 (2001).
5. Poignard, R et al. Neutralizing antibodies have limited effects on the control of established HIV-1 in vivo. Immunity 10, 431-438 (1999).
6. Parren, P. W. H. I., Moore, J. P., Burton, D. R. & Sattentau, Q. J. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13 (Suppl. A), S137-S162 (1999).
7. Kuiken, C. L. et al. (eds) Human Retroviruses and AIDS 2000: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences (Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, 2000).
8. Myers, G. & Lenroot, R. HIV glycosylation: What does it portend? AIDS Res. Hum. Retroviruses 8, 1459-1460 (1992).
9. Ramratnam, B. et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354, 1782-1785 (1999).
10. Markowitz, M. et al. A novel antiviral intervention results in a more accurate assessment of HIV-1 replication dynamics and T-cell decay in vivo. J. Virol. (in the press).
11. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
12. Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205-211 (1997).
13. Wei, X. et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896-1905 (2002).
14. Kwong, P. D. et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 8, 1329-1339 (2000).
15. Wyatt, R. et al. The antigenic structure of the ofthe human immunodeficiency virus gp120 envelope glycoprotein. Nature 393, 705-711 (1998).
16. Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens and immunogens. Science 280, 1884-1888 (1998).
17. Poignard, P., Saphire, E. O., Parren, P. W. H. I. & Burton, D. R. GP120: Biologic aspects of structural features. Annu. Rev. Immunol. 19, 253-274 (2001).
18. Kwong, P. D., Wyatt, R., Sattentau, Q. J., Sodroski, J. & Hendrickson, W. A. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotien of human immunodeficiency virus. J. Virol. 74, 1961-1972 (2000).
19. Mizuochi, T. et al. Diversity of oligosaccharide structures on the envelope glycoprotien gp120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. J. Biol. Chem. 265, 8519-8524 (1990).
20. Scanlan, C. N. et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α → 2 mannose residues on the outer face of gp120. J. Virol. 76, 7306-7321 (2002).
21. Sanders, R. W. et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76, 7293-7305 (2002).
22. Gorny, M. K. et al. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. 76, 9035-9045 (2002).
23. Kolchinsky, P., Kiprilov, E. & Sodroski, J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J. Virol. 75, 2041-2050 (2001).
24. Chackerian, B., Rudensey, L. M. & Overbaugh, J. Specific N-linked and O-linked glycosylation modifications in the envelope VI domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J. Virol. 71, 7719-7727 (1997).
25. Back, N. K. et al. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199, 431-438 (1994).
26. Reitter, J. N., Means, R. E. & Desrosiers, R. C. A role for carbohydrates in immune evasion in AIDS. Nature Med. 4, 679-684 (1998).
27. Kwong, P. D. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682 (2002).
28. Stewart, J. J., Watts P. & Litwin, S. Profile of a Quasispecies: The Selected Mutational Landscape of HIV and Influenza (Vrije Univ., Amsterdam, 1999).
29. Nowak, M. A. & May, R. M. Viral Dynamics (Oxford Univ. Press, Oxford, 2000).
30. Richman, D., Wrin, T., Little, S. & Petropoulos, C. Rapid evolution of the neutralizing antibody response to human immunodeficiency virus type 1 infection. Proc. Natl Acad. Sci. USA (in the press).